{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5","upperLimit":"29","value":"17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"Recurrent or progressive malignancy will be assessed with the use of cumulative incidence plots. Recurrent malignancy will be defined by hematologic criteria. Recurrent malignancy will also be defined as any unplanned medical intervention designed to prevent progression of malignant disease in patients who have molecular, cytogenetic or flow-cytometric evidence of malignant cells after transplantation.","dispersionType":"95% Confidence Interval","groups":[{"description":"PREPARATIVE REGIMEN: Patients receive TBI BID on days -4 or -3 to -1. Some patients also receive fludarabine IV daily on days -5 to -2 and busulfan IV over 3 hours QD or over 2 hours every 6 hours on days -5 to -2. Patients may also undergo CNS prophylaxis, testicular irradiation, and/or involved field irradiation as per standard practice.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 per standard practice.\n\nGVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on days 56-126.\n\ncyclophosphamide: Given IV\n\ncyclosporine: Given IV\n\nperipheral blood stem cell transplantation: Undergo allogeneic PBSCT\n\ntotal-body irradiation: Undergo TBI\n\nfludarabine phosphate: Given IV\n\nbusulfan: Given IV\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic PBSCT","id":"OG000","title":"Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"At 2 years","title":"Persistent or Recurrent Malignancy After HCT","type":"SECONDARY","unitOfMeasure":"percentage of patients"}